FDA Updates the Clinical Outcome Assessment Compendium

Clinical Outcome Assessments (COAs) are the measures of the clinical response to a treatment as observed by a patient, their physician, an independent observer, or an objective measure of the patient’s performance following treatment with a drug or biologic. COAs are closely related to patient focused drug development where clinically relevant outcomes can and have … Read more

Did the EUA for Covid Tests, Kill the 510k for them?

Why is there only one diagnostic test for Covid cleared by FDA under the 510k pathway after almost 2 years of the pandemic? FDA has granted emergency use authorizations (EUA) to 423 Covid tests, but it has only given one device 510k clearance, that too in March of this year, 9 months ago. The 510k … Read more

If You Ever Wanted to File a FOI Request with FDA: Forget it. 

For those who have tried, sending a Freedom of Information (FOI) request to FDA is like dropping a coin in a wishing well and then hoping for your prayers to be answered. FDA recently provided a rare glimpse into its FOI process in response to a court case and it would come as no surprise … Read more

FDA’s EUA for Covid LDTs Has Minimal Impact on Most LDTs 

This week FDA announced that it is going to require emergency use authorizations (EUA) for Lab Developed Tests (LDTs) intended for Covid diagnosis summarily reversing a decision last August that LDTs don’t need EUA. While this may seem like a major decision, it is not. The announcement is very specific to RT-PCR tests for Covid, … Read more

RWE Shows that Short-Course Antibiotic Treatment is Better and Safer

Real world data (RWD) and the resulting real world evidence (RWE) can provide unique and valuable information, otherwise hard to generate, on best practices for patient treatment in real-world health care settings. FDA supported two RWD studies, one in adults and the other in pediatric populations, to evaluate the duration of the antibiotic treatments for … Read more

FDA May Soon Require Dose Findings Studies for Oncology Product Approval 

Most cancer drugs are clinically evaluated at the highest dose possible, the Maximum Tolerated Dose (MTD), with the assumption that more is better. A white paper co-authored by several FDA oncology drug officials argues that the MTD approach is no longer appropriate and that prior to conducting registration studies, sponsors should conduct dose-finding studies to … Read more

Who’s Responsible for Food Safety: FDA, CDC or USDA?

FDA has several programs for assuring food safety and often publishes on various food safety initiatives. But USDA and CDC also play in role in regulating food supply and monitoring for food-borne infections. An article this week describes how despite multiple regulations and programs, several food-borne illnesses go unchecked. According to CDC, about 48 million … Read more

Did Biogen Bribe Doctors or Play it Fairly? 

Companies developing new drugs often hire outside subject matter experts (SMEs) to advise on the development strategies, build scientific consensus, and advocate for the product to others. And the SMEs are compensated for their time. But does getting paid for their time compromise the integrity of the SMEs? A news item floating in the media … Read more

10 Principles for Machine Learning or AI Medical Devices from FDA

Although FDA has approved about 343 medical devices using Artificial Intelligence (AI) and Machine Learning (ML) technologies, a much larger number of devices using such technologies are used in general health awareness applications and do not require FDA’s review or approval for launch. These are mostly apps or software that collect data about real world … Read more